click
Contact

Tag: TSL2402

A Note of Appreciation, A Mark of Recognition | Medicilon Supports Partner Tasly in Obtaining Clinical Trial Approval for TSL2402 Tablets

Preclinical CRO

Recently, Tianjin Tasly Saint Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Tasly Pharmaceutical Group Co., Ltd. (Stock Code: 600535), received the Notice of Approval for Drug Clinical Trial (No. 2026LP02559) for TSL2402 Tablets issued by the National Medical Products Administration (NMPA), authorizing the initiation of clinical trials for the drug.As Tasly’s partner, Medicilon has received […]

Contact

Search Medicilon

Preclinical CRO

Breaking New Ground in Alzheimer’s Disease! Medicilon Supports Hengrui Pharma’s SHR-3201 Injection to Secure Clinical Trial Approval

Read more
Preclinical CRO

Breaking the “King of Cancer”: First-in-Class ADC MC001. Medicilon Supports Partner Medicovestor to Secure FDA IND Clearance

Read more
Preclinical CRO

Medicilon’s Dr. Chunlin Chen Engages FDA Experts at SAPA-DC Annual Conference to Discuss Global IND Development and NAMs Technologies for Innovative Medicines

Read more

Contact Medicilon

Name(Required)
Address(Required)